Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
Belite Bio (BLTE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
Foundation Fighting Blindness to Host United in Vision 2026 Conference in Partnership with Retina International World Congress
Belite Bio (BLTE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.